Abstract
Women who experience pre-eclampsia or hypertension during pregnancy may have a reduced risk for breast cancer later in life. The evidence is based on case–control studies, and here we report the results of a cohort study exploring the link between pre-eclampsia and gestational hypertension diagnosed in the first pregnancy and subsequent risk for breast cancer. We combined information from the Medical Birth Registry and the Cancer Registry in Norway, which are both nation-wide. Between 1967, when the birth registry was established, and 1998, 694 657 women were recorded with a first birth, and classified according to whether pre-eclampsia and/or hypertension was diagnosed in the first pregnancy. Linkage to the Norwegian Cancer Registry identified 5474 new cases of breast cancer diagnosed subsequently to their first delivery. Compared to other parous women, women with pre-eclampsia and/or hypertension diagnosed in their first pregnancy had 19% lower risk (95% confidence interval, 9 to 29%) for breast cancer, after adjustment for attained age, calendar period of diagnosis, age at first birth, and parity. This result was similar for term and preterm deliveries, across the range of offspring birth weight, and for pre- and postmenopausal women. These results suggest that the pathophysiology surrounding pre-eclampsia and gestational hypertension plays an important role in breast cancer etiology. A better understanding of the underlying processes could provide an insight into the pathogenesis of breast cancer.
Similar content being viewed by others
Main
Several risk factors for breast cancer have been identified (Kelsey, 1993), but few of them are linked to identifiable mechanisms that allow a clear insight into the natural history of breast cancer. There have been studies indicating that pre-eclampsia or hypertension in pregnancy is associated with subsequent reduction in breast cancer risk in the mother (Polednak and Janerich, 1983; Troisi et al, 1998; Thompson et al, 1989; Cohn et al, 2001). If confirmed, this association could be particularly useful in understanding the pathogenesis of breast cancer (Hoover and Troisi, 2001), because pre-eclampsia has an identifiable, if not yet fully identified, pathophysiology (Roberts and Cooper, 2001). The earlier investigations of the association of pre-eclampsia or pregnancy hypertension with breast cancer risk (Polednak and Janerich, 1983; Thompson et al, 1989; Troisi et al, 1998; Cohn et al, 2001), however, have all had a case–control design that is not immune to subtle biases. We report here the results of a cohort study exploring the link between pre-eclampsia and/or hypertension in pregnancy and subsequent breast cancer risk in the mother.
Materials and methods
Data were derived from the Norwegian Medical Birth Registry that comprises all births since 1967, and the Norwegian Cancer Registry, which has registered incident cancers since 1953. Midwives and doctors have to fill in a standardised form to notify the birth registry about each birth that takes place in the country, and the reporting of cancer by doctors or hospital departments to the cancer registry is also mandatory. The unique identification number of Norwegian citizens enabled linkage between the birth registry and the cancer registry for cancer follow-up.
We have identified cases of pre-eclampsia and/or hypertension induced by pregnancy as indicated in the standardised form, and the women were accordingly categorised as having been diagnosed with at least one of these conditions (Lie et al, 1998). In the analyses, we further subdivided the women according to whether they had a premature delivery (<37 weeks' gestation) or not, according to offspring's birth weight (in three categories: small, appropriate, or large for gestation), and according to age at diagnosis (cut-off at 50 years to approximate pre- and postmenopausal status).
We used each woman's identification number to link the women registered at the medical birth registry to the national cancer registry in order to identify women who had developed cancer subsequent to giving birth. In total, 756 414 women have been recorded with a first birth in the birth registry between 1967 and 1998. Of these, 1556 women were excluded from analysis, either because they had a diagnosis of cancer recorded prior to their first birth, or because they had emigrated and could not be traced during follow-up. We also excluded 60 201 women who had incomplete information on offspring birth weight or length of gestation at birth. Thus, we have followed 694 657 women from their first birth until the diagnosis of cancer, until death from any cause, or to the end of follow-up (December 31, 1998), whichever occurred first.
We compared breast cancer risk in women who had experienced pre-eclampsia and/or hypertension induced by their first pregnancy with the risk in other parous women, and adjusted for attained age (nine categories), calendar period of diagnosis (three categories), age at first birth (five categories), and total number of births (five categories). In the multivariate analyses, we applied Poisson regression modelling, using the Epicure software (Epicure, Seattle, WA, USA: Hirosoft Int Corp, 1993), and we used SPSS, version 10.05 (SPSS, Inc., Chicago, IL, USA), for the descriptive analyses.
Results
During follow-up, 5474 cases of breast cancer were diagnosed among the 694 657 parous women. Of these cases, 280 occurred among women who were diagnosed with pre-eclampsia and/or hypertension in their first pregnancy. These women had a 19% lower risk of subsequent breast cancer than the remaining women (rate ratio 0.81, 95% confidence interval 0.71 to 0.91), after adjustment for attained age, calendar period of diagnosis, age at first birth, and parity (Table 1).
We explored whether the association between pre-eclampsia and breast cancer risk could be modified by length of gestation (preterm or term delivery), offspring birth weight, or the woman's age (cut-off at 50 years). The results show that the pre-eclampsia-related reduction of breast cancer risk did not substantially differ across these subgroups (Table 2).
Discussion
We found that women who were diagnosed with pre-eclampsia and/or hypertension in their first pregnancy were at reduced risk of breast cancer, compared to other women who did not develop pre-eclampsia or hypertension during their first pregnancy. The inverse association has also been found in the previously reported case–control studies (Polednak and Janerich, 1983; Troisi et al, 1998; Thompson et al, 1989; Cohn et al, 2001).
The prospective nature of this study all but excludes selection or information bias as plausible explanations for the findings, and the large number of women makes it unlikely that chance can play an important role.
The clinical manifestations of pre-eclampsia are heterogeneous, and this could indicate that the condition comprises different biological entities (Ness and Roberts, 1996). If so, one might expect that the association between pre-eclampsia and breast cancer risk would differ among subtypes of pre-eclampsia. However, by exploring the association between different characteristics of pre-eclampsia and breast cancer risk, we found that the reduced risk for breast cancer was consistent between term and preterm deliveries, across the range of the offspring's birth weight, and between pre- and postmenopausal women.
Our analysis focused on the first pregnancy, with adjustment for total ascertainable parity. Although less common, some women will have developed pre-eclampsia or hypertension also during higher order pregnancies, and because of this, the pre-eclampsia-related protection against breast cancer in our study could have been somewhat underestimated.
A central characteristic of pre-eclampsia is an abnormal implantation that has been attributed to a shallow connection between the placenta and the endometrium (Roberts and Cooper, 2001). A combination of genetic susceptibility and abnormal placentation is thought to constitute the basis for pre-eclampsia, and clinically, the syndrome is characterised by hypertension and proteinuria. In women who develop pre-eclampsia, there may be a disturbance in the fundamental balance between steroid and other pregnancy hormones, with relatively lower oestrogen, and higher androgen levels (Innes and Byers, 1999). Since pre-eclampsia conveys some protection against breast cancer risk, a better understanding of its pathophysiology could also provide an insight into the pathogenesis of breast cancer.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Cohn BA, Cirillo PM, Christianson RE, van den Berg BJ, Siiteri PK (2001) Placental characteristics and reduced risk of maternal breast cancer. J Natl Cancer Inst 93: 1133–1140
Hoover RN, Troisi RJ (2001) Understanding mechanisms of breast cancer prevention. (editorial)J Natl Cancer Inst 93: 1119–1120
Innes KE, Byers TE (1999) Preeclampsia and breast cancer risk. Epidemiology 10: 722–732
Kelsey JL (1993) Breast cancer epidemiology: summary and future directions. Epidemiol Rev 15: 256–263
Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie NE, Irgens LM (1998) Foetal and maternal contributions to risk of preeclampsia: population-based study. BMJ 316: 1343–1347
Ness RB, Roberts JM (1996) Heterogeneous causes constituting the single syndrome of preeclampsia: A hypothesis and its implications. Am J Obstet Gynecol 175: 1365–1370
Polednak AP, Janerich DT (1983) Characteristics of first pregnancy in relation to early breast cancer. A case–control study. J Reprod Med 28: 314–318
Roberts J, Cooper DW (2001) Pathogenesis and genetics of pre-eclampsia. Lancet 357: 53–56
Thompson WD, Jacobsen H, Negrini B, Janerich DT (1989) Hypertension, pregnancy, and risk of breast cancer. J Natl Cancer Inst 81: 1571–1574
Troisi R, Weiss HA, Hoover RN, Potischman N, Swanson CA, Brogan DR, Coates RJ, Gammon MD, Malone KE, Daling JR, Brinton LA (1998) Pregnancy characteristics and maternal risk of breast cancer. Epidemiology 9: 641–647
Acknowledgements
We thank the women who participated in this study, and the Norwegian Medical Research Council and the Norwegian Cancer Society for financial support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Vatten, L., Romundstad, P., Trichopoulos, D. et al. Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer 87, 971–973 (2002). https://doi.org/10.1038/sj.bjc.6600581
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6600581
Keywords
This article is cited by
-
A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia
Breast Cancer Research and Treatment (2023)
-
Hypertensive conditions of pregnancy, preterm birth, and premenopausal breast cancer risk: a premenopausal breast cancer collaborative group analysis
Breast Cancer Research and Treatment (2023)
-
Hypertensive diseases of pregnancy and risk of breast cancer in the Black Women’s Health Study
Breast Cancer Research and Treatment (2022)
-
Maternal reproductive hormones and angiogenic factors in pregnancy and subsequent breast cancer risk
Cancer Causes & Control (2019)
-
Long-term impact of preeclampsia on maternal endometrial cancer risk
British Journal of Cancer (2016)